Prestige Consumer Healthcare Inc. (PBH) Moves to Stabilize Eye Care Amid 2025 Headwinds

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Prestige Consumer Healthcare Inc. stands amongst them.

Prestige Consumer Healthcare Inc. (NYSE:PBH), a global developer of OTC health and personal care products, is taking strategic steps to secure growth in its eye care business amid operational challenges in 2025.

In August 2025, Prestige Consumer Healthcare Inc. (NYSE:PBH) acquired Pillar5 Pharma, a key supplier of multi-dose sterile ophthalmic products, including those for its Clear Eyes brand. The acquisition aims to address previous supply constraints that limited shipments and revenue, ensuring reliable production and supporting long-term expansion in the eye care segment. The firm expects supply improvements to accelerate in the second half of 2025, reversing earlier declines.

Despite a 6.6% year-over-year revenue decline in Q1 2026, Prestige Consumer Healthcare Inc. (NYSE:PBH) reported momentum across other business segments, including international OTC healthcare growth and improved gross margins. CEO Ron Lombardi emphasized that integrating Pillar5’s capabilities strengthens the Clear Eyes franchise and overall business resilience.

While we acknowledge the potential of PBH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.